GLP-1 C | GLP-1 1S

CagriSema is a fixed-dose, co-formulated therapy combining Cagrilintide (2.4 mg), a long-acting amylin analog, with Semaglutide (2.4 mg), a GLP-1 receptor agonist. Delivered as a single once-weekly subcutaneous injection, CagriSema leverages complementary pathways for appetite regulation, glycemic control, and metabolic optimization.

Cagrilintide – an amylin and calcitonin receptor agonist with a half-life of ~184 hours, enhancing satiety, delaying gastric emptying, and suppressing postprandial glucagon through brainstem signaling.
Semaglutide – a GLP-1 receptor agonist with a half-life of ~158 hours, driving glucose-dependent insulin secretion, further glucagon suppression, and hypothalamic appetite regulation.

The combination provides dual appetite suppression and superior metabolic outcomes, with clinical efficacy approaching that of bariatric surgery.

Weight Loss Superiority: Up to 22.7% mean bodyweight reduction at 68 weeks.
High Responder Rate: ~60% of patients achieved ≥20% weight loss.
Glycemic Control: Mean HbA1c reduction of 2.07%; 74% achieved HbA1c ≤6.5%.
Dual Appetite Suppression: Targeting both homeostatic and hedonic eating pathways.
Cardiovascular Benefits: Reductions in systolic blood pressure and improvements in lipid profile.
Diabetes Remission Potential: Durable improvements in weight and glycemic indices.
Favorable Tolerability: Mostly GI-related adverse events with relatively low discontinuation.
Flexible Dosing: Clinically meaningful weight loss achieved even below maximum dosing levels.

Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. Published online June 22, 2025. doi:10.1056/NEJMoa2502081
Davies MJ, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. Published online June 22, 2025. doi:10.1056/NEJMoa2502082
Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01163-7
Dutta D, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (CagriSema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024;28(5):436-444. doi:10.4103/ijem.ijem_45_24
Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10257):1736-1748. doi:10.1016/S0140-6736(21)00845-X

$150.00

Per Unit

In stock